Editas Medicine (EDIT)

• Market cap: $111M
• 1 day: 3.91%
• 5 days: 0.00%
• 1 month: 1.53%
• 3 months: 9.92%
• 6 months: -64.63%
• Year to date: 1.53%
• 1 year: -76.25%
• 5 years: -94.37%
• 10 years: -92.69%
• Sector: Healthcare
• Industry: Biotechnology

About: Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Employees: 226

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

7% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 57

2% more call options, than puts

Call options by funds: $396K | Put options by funds: $388K

5.03% less ownership

Funds ownership: 66.84% [Q3] → 61.82% (-5.03%) [Q4]

11% less funds holding

Funds holding: 227 [Q3] → 202 (-25) [Q4]

36% less first-time investments, than exits

New positions opened: 37 | Existing positions closed: 58

65% less capital invested

Capital invested by funds: $188M [Q3] → $64.8M (-$123M) [Q4]